Platinum
- Generic Name
- Platinum
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- Pt
- CAS Number
- 7440-06-4
- Unique Ingredient Identifier
- 49DFR088MY
- Background
Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and Pancreatic Large Cell Neuroendocrine Carcinoma, among others. Platinum has been investigated for the treatment and supportive care of Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Primary Cancer, Non Small Cell Lung Cancer, and Primary Peritoneal Carcinoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage Non-Small Cell Lung Cancer
AstraZeneca presented interim results from the NeoCOAST-2 Phase 2 study at the 2024 World Conference on Lung Cancer, showing promising outcomes for early-stage non-small cell lung cancer patients across treatment arms. Monalizumab, in combination with durvalumab and platinum-based chemotherapy, demonstrated higher pathological complete response and major pathological response rates compared to the approved regimen, with a manageable safety profile.
Related Clinical Trials:
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the ...
HUTCHMED announces new data from studies of compounds to be presented at 2024 WCLC and ESMO Congresses. Key findings include positive results from the FLOWERS study, showing deeper and more durable response with osimertinib plus savolitinib in EGFRm, MET-aberrant advanced NSCLC patients compared to osimertinib monotherapy.
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
Merck discontinues Phase 3 KeyVibe-008 trial evaluating a fixed-dose combination of vibostolimab and pembrolizumab in extensive-stage small cell lung cancer (ES-SCLC) patients due to meeting pre-specified futility criteria for overall survival (OS). Patients in the combination arm experienced higher rates of adverse events (AEs) and immune-related AEs compared to the control arm. Ongoing comprehensive analysis and further clinical development program expansions are noted.
Related Clinical Trials:
New approaches for targeting platinum-resistant ovarian cancer
Platinum resistance in ovarian cancer, especially high-grade serous carcinoma, involves complex mechanisms including DNA repair restoration, reduced platinum accumulation, and tumor microenvironment changes. Current treatments have limited efficacy, highlighting the need for clinical trials combining chemotherapy, immunotherapy, and targeted therapies. Future research should focus on understanding disease biology and improving patient outcomes.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath